Natalia Tovar

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka et al. · Blood · 2021 · 98 citations

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Uma Borate, Jordi Esteve, Kimmo Porkka et al. · Blood · 2019 · 85 citations

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Aina Oliver‐Caldés, Verónica González‐Calle, Valentín Cabañas et al. · The Lancet Oncology · 2023 · 76 citations · Full text

Hematological Malignancy, Medicine, Immunology +7

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Nico Gagelmann, Danai Dima, Maximilian Merz et al. · Journal of Clinical Oncology · 2024 · 70 citations · Full text

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka et al. · Blood · 2020 · 68 citations